Free Trial
NASDAQ:FENC

Adherex Technologies Q3 2025 Earnings Report

Adherex Technologies logo
$6.72 +0.07 (+1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$6.72 0.00 (0.00%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adherex Technologies EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Adherex Technologies Revenue Results

Actual Revenue
$12.46 million
Expected Revenue
$13.43 million
Beat/Miss
Missed by -$971.00 thousand
YoY Revenue Growth
N/A

Adherex Technologies Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Adherex Technologies' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adherex Technologies Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Adherex Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

View Adherex Technologies Profile